Results 261 to 270 of about 13,963,189 (308)
Some of the next articles are maybe not open access.
Second-line therapy for advanced colorectal carcinoma
Current Oncology Reports, 2005The past decade has witnessed considerable advances in the treatment of colorectal cancer (CRC). The emergence and integration into clinical practice of new cytotoxic agents, such as irinotecan and oxaliplatin, has had a significant impact on outcomes from advanced CRC with median survivals of 18 to 21 months now achievable. Improvements in survival as
Naureen, Starling, David, Cunningham
openaire +2 more sources
Second line therapy with cetuximab in NSCLC
Journal of Clinical Oncology, 200617145 Background: EGFR is overexpressed in different solid tumors and in 50–80% of NSCLC. The neoplastic growth and metastatic process is correlated with EGFR overexpression, so that it became the target of a new therapeutic approach. The monoclonal antibody (Mab) against the extracellular domain represent the most innovated method of EGFR inaction ...
R. Buosi +5 more
openaire +1 more source
First- and second-line therapy of metastatic colorectal cancer
Expert Review of Anticancer Therapy, 2006In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer. In 2006, 148,610 colorectal cancer cases are expected in the USA, with 55,170 deaths expected from this disease. After years of stagnation, the treatment of metastatic colorectal cancer has recently made dramatic advances.
Shelby, Terstriep, Axel, Grothey
openaire +2 more sources
Second-line therapies in advanced biliary tract cancers
The Lancet Oncology, 2020Biliary tract cancers constitute approximately 3% of gastrointestinal malignancies with poor prognosis. Surgical therapy is the main form of treatment in localised disease; however, for patients with advanced stage or unresectable disease, locoregional and systemic chemotherapeutics are primary treatment options. Although the combination of gemcitabine
Sri Harsha, Tella +3 more
openaire +2 more sources
Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?
The American Journal of Gastroenterology, 2008In patients with autoimmune hepatitis, efficient immunosuppressive therapy is essential to avoid progression to cirrhosis. There is no established second line therapy for patients failing standard therapy with steroids and azathioprine. The aim of this study was to examine the possible role of mycophenolate mofetil (MMF) as second line treatment of ...
Elke M, Hennes +11 more
openaire +2 more sources
Second-line therapy for refractory renal-cell carcinoma
Critical Reviews in Oncology/Hematology, 2012In the last 5 years inhibitors of the VEGF/VEGFR and mTOR pathways have dramatically changed the therapeutic approach to metastatic renal cancer. Randomized controlled trials have shown that six targeted agents--sorafenib, sunitinib, temsirolimus, bevacizumab, everolimus and pazopanib--are able to improve patient outcome. Even if the choice of drug for
Fable, Zustovich +3 more
openaire +2 more sources
Second-line-Therapie des Ovarialkarzinoms
Oncology Research and Treatment, 2000Despite the high response rate of ovarian cancer patients, 70% of them will relapse and have to be considered as candidates for second-line treatment. If the relapse is diagnosed within the first year after initial standard treatment with paclitaxel/carboplatinum, the tumor has to be classified as platinum-resistant disease with an expected response ...
openaire +1 more source
Treosulfan as an Effective Second-Line Therapy in Ovarian Cancer
Gynecologic Oncology, 1998Despite radical surgery and aggressive platinum-containing primary chemotherapy, the outcome of patients with advanced ovarian cancer remains extremely poor; most of them suffer from recurrent or progressive disease. These patients should be treated with an effective second-line therapy showing only few toxic side effects so as not to affect quality of
M, Gropp, W, Meier, H, Hepp
openaire +2 more sources
Targeted agents in second-line bladder cancer therapy
Anti-Cancer Drugs, 2012The treatment of metastasized urothelial cancer has been evolving in recent years. In particular, in the second-line setting after the failure of platinum-containing therapy, options are few and besides vinflunine, the recently approved standard in Europe, well-designed highly selective clinical trials may be possible alternatives for patients in this ...
Gerullis, Holger +2 more
openaire +3 more sources
Prognostic accuracy in second-line renal cancer therapy
The Lancet Oncology, 2015Lancet Oncology, The - In Press.Proof corrected by the author Available online since vendredi 13 fevrier ...
openaire +2 more sources